What is HC Wainwright's Forecast for AVXL Q1 Earnings?

Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Anavex Life Sciences in a research report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will earn ($0.18) per share for the quarter. HC Wainwright has a "Buy" rating and a $42.00 price target on the stock. The consensus estimate for Anavex Life Sciences' current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences' Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.66) EPS.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03.

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Anavex Life Sciences Stock Performance

AVXL stock traded down $0.33 during mid-day trading on Wednesday, reaching $8.35. The company had a trading volume of 1,126,061 shares, compared to its average volume of 957,895. The company has a market capitalization of $710.25 million, a price-to-earnings ratio of -15.18 and a beta of 0.69. The firm has a fifty day simple moving average of $9.97 and a 200 day simple moving average of $7.79. Anavex Life Sciences has a fifty-two week low of $3.25 and a fifty-two week high of $14.44.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AVXL. Nwam LLC purchased a new position in shares of Anavex Life Sciences in the 3rd quarter valued at about $5,172,000. Invesco Ltd. increased its holdings in shares of Anavex Life Sciences by 2,419.8% in the 4th quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company's stock valued at $6,606,000 after acquiring an additional 590,639 shares during the last quarter. Pier Capital LLC purchased a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $4,746,000. Essential Planning LLC. purchased a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $4,437,000. Finally, Wellington Management Group LLP purchased a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $1,704,000. Hedge funds and other institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.